Sat, Mar 2nd 2024
LimmaTech Biologics AG receives a $2.2 million boost from CARB-X to combat antibiotic-resistant gonorrhea with a promising vaccine, aiming to alleviate a global health threat.
LimmaTech Biologics AG, a Swiss company, focusing on a pivotal vaccine against neisseria gonorrhoea claims they have been granted a significant $2.2 million investment from CARB-X.
LimmaTech’s CEO, emphasises the dire need for an efficacious vaccine to combat the escalating drug resistance observed in gonorrhea cases. The proprietary technology behind their vaccine could be a game-changer in the battle against bacterial infectious diseases.
This sexually transmitted infection (STI), ranking as the second most reported globally, affected roughly 82 million people in 2020, leading to severe health consequences like infertility and increased HIV risk. The stealth nature of this disease, often asymptomatic, highlights the hidden health burden it imposes.
LimmaTech’s vaccine aims to counteract the growing menace of antibiotic-resistant strains of Neisseria gonorrhoeae, which have outmaneuvered nearly all antibiotics, leaving ceftriaxone as the sole remaining effective treatment.
The vaccine’s development, aims to induce an immune response across various bacterial strains, a critical factor for ensuring accessibility and affordability in lower-income regions.
Since its establishment in 2016, CARB-X has been instrumental in reinvigorating the stagnant antibiotic pipeline, supporting over 90 R&D projects across 13 countries. 18 projects they have backed lead to clinical trials and the introduction of two diagnostic products to the market.
LimmaTech’s vaccine, is the sixth project funded in the 2022-2023 cycle, exemplifies CARB-X’s ongoing efforts to address critical gaps in the antibacterial science.
The consortium funding this research includes prestigious entities like the U.S. Health Department, Wellcome, and the Novo Nordisk Foundation, among others. This collaborative effort underscores the global commitment to combating the threat of antibiotic-resistant infections.
English 
German 
French 
Spanish 
Arabic